Studio di fase III, in aperto, su Dato-DXd di prima linea in combinazione con Rilvegostomig per il NSCLC avanzato non squamoso con elevata espressione di PD-L1 (TC ≥ 50%) e senza alterazioni genomiche utilizzabili (TROPION-Lung10)
Uno studio globale di Fase III, randomizzato, in aperto, su Datopotamab Deruxtecan (Dato-DXd) in combinazione con Rilvegostomig o Rilvegostomig in monoterapia rispetto a Pembrolizumab in monoterapia per il trattamento di prima linea di partecipanti con NSCLC non squamoso localmente avanzato o metastatico con elevata Espressione PD-L1 (TC ≥ 50%) e senza alterazioni genomiche utilizzabili (TROPION-Lung10)
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a Phase III, randomized, open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig monotherapy compared with Pembrolizumab monotherapy for the first-line treatment of participants with locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: AstraZeneca Clinical Study Information Center
- Numero di telefono: 1-877-240-9479
- Email: information.center@astrazeneca.com
Luoghi di studio
-
-
-
Birtinya, Australia, 4575
- Ritirato
- Research Site
-
Blacktown, Australia, 2148
- Ritirato
- Research Site
-
Clayton, Australia, 3168
- Reclutamento
- Research Site
-
Gosford, Australia, 2250
- Reclutamento
- Research Site
-
Melbourne, Australia, 3000
- Ritirato
- Research Site
-
South Brisbane, Australia, QL 4101
- Reclutamento
- Research Site
-
Wodonga, Australia, 3690
- Reclutamento
- Research Site
-
-
-
-
-
Innsbruck, Austria, 6020
- Reclutamento
- Research Site
-
Krems, Austria, 3500
- Reclutamento
- Research Site
-
Linz, Austria, 4020
- Reclutamento
- Research Site
-
Rankweil, Austria, 6830
- Reclutamento
- Research Site
-
Vienna, Austria, 1210
- Reclutamento
- Research Site
-
Vienna, Austria, 1140
- Reclutamento
- Research Site
-
Wels, Austria, 4600
- Ritirato
- Research Site
-
-
-
-
-
Anderlecht, Belgio, 1070
- Ritirato
- Research Site
-
Bruges, Belgio, 8000
- Reclutamento
- Research Site
-
Hasselt, Belgio, 3500
- Reclutamento
- Research Site
-
La Louvière, Belgio, 7100
- Reclutamento
- Research Site
-
Liège, Belgio, 4000
- Reclutamento
- Research Site
-
-
-
-
-
Barretos, Brasile, 14784-400
- Reclutamento
- Research Site
-
Curitiba, Brasile, 80730-150
- Reclutamento
- Research Site
-
Florianópolis, Brasile, 88034-000
- Reclutamento
- Research Site
-
Ipatinga, Brasile, 35162-189
- Reclutamento
- Research Site
-
Natal, Brasile, 59075-740
- Reclutamento
- Research Site
-
Porto Alegre, Brasile, 91350-200
- Reclutamento
- Research Site
-
Rio de Janeiro, Brasile, 22211-230
- Reclutamento
- Research Site
-
Santa Maria, Brasile, 97015-450
- Reclutamento
- Research Site
-
São Paulo, Brasile, 01221-020
- Reclutamento
- Research Site
-
Taubaté, Brasile, 12030-200
- Reclutamento
- Research Site
-
-
-
-
-
Chicoutimi, Canada, G7H 5H6
- Reclutamento
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Canada, VSZ 4E6
- Reclutamento
- Research Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Ritirato
- Research Site
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Reclutamento
- Research Site
-
-
Ontario
-
London, Ontario, Canada, N6A 4L6
- Reclutamento
- Research Site
-
Newmarket, Ontario, Canada, L3Y 2P9
- Ritirato
- Research Site
-
Oshawa, Ontario, Canada, L1G 2B9
- Reclutamento
- Research Site
-
Toronto, Ontario, Canada, M4N 3M5
- Ritirato
- Research Site
-
-
Quebec
-
Lévis, Quebec, Canada, G6V 0B8
- Reclutamento
- Research Site
-
Montreal, Quebec, Canada, H4J 1C5
- Reclutamento
- Research Site
-
Montreal, Quebec, Canada, H3T 1E2
- Reclutamento
- Research Site
-
Montreal, Quebec, Canada, H3T 1M5
- Ritirato
- Research Site
-
Rimouski, Quebec, Canada, G5L 5T1
- Reclutamento
- Research Site
-
Trois-Rivières, Quebec, Canada, G8Z 3R9
- Reclutamento
- Research Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Reclutamento
- Research Site
-
-
-
-
-
Beijing, Cina, 100142
- Reclutamento
- Research Site
-
Beijing, Cina, 101149
- Reclutamento
- Research Site
-
Changchun, Cina, 130000
- Reclutamento
- Research Site
-
Changsha, Cina, 410013
- Reclutamento
- Research Site
-
Chengdu, Cina, 610000
- Reclutamento
- Research Site
-
Chengdu, Cina, 610041
- Reclutamento
- Research Site
-
Chongqing, Cina, 400030
- Reclutamento
- Research Site
-
Fuzhou, Cina, 350014
- Reclutamento
- Research Site
-
Guangzhou, Cina, 510080
- Reclutamento
- Research Site
-
Hangzhou, Cina, 310006
- Reclutamento
- Research Site
-
Hangzhou, Cina, 310022
- Reclutamento
- Research Site
-
Hangzhou, Cina, 310016
- Reclutamento
- Research Site
-
Harbin, Cina, 150049
- Reclutamento
- Research Site
-
Hefei, Cina, 230601
- Reclutamento
- Research Site
-
Hefei, Cina, 230031
- Ritirato
- Research Site
-
Jinan, Cina, 250117
- Reclutamento
- Research Site
-
Jining, Cina, 272011
- Ritirato
- Research Site
-
Kunming, Cina, 650118
- Reclutamento
- Research Site
-
Lanzhou, Cina, 730000
- Reclutamento
- Research Site
-
Linhai, Cina, 317000
- Reclutamento
- Research Site
-
Linyi, Cina, 276001
- Reclutamento
- Research Site
-
Nanjing, Cina, 210009
- Reclutamento
- Research Site
-
Nanning, Cina, 530021
- Reclutamento
- Research Site
-
Nanning, Cina, 530000
- Reclutamento
- Research Site
-
Shanghai, Cina, 200032
- Reclutamento
- Research Site
-
Shanghai, Cina, 200030
- Reclutamento
- Research Site
-
Shanghai, Cina, 200433
- Reclutamento
- Research Site
-
Shenyang, Cina, 110022
- Reclutamento
- Research Site
-
Taiyuan, Cina, 030000
- Reclutamento
- Research Site
-
Tianjin, Cina, 300060
- Reclutamento
- Research Site
-
Wenzhou, Cina, 325000
- Reclutamento
- Research Site
-
Wuhan, Cina, 430022
- Reclutamento
- Research Site
-
Wuhan, Cina, 430030
- Reclutamento
- Research Site
-
Wuhan, Cina, 430010
- Reclutamento
- Research Site
-
Wuhan, Cina, 430000
- Reclutamento
- Research Site
-
Xi'an, Cina, 710061
- Reclutamento
- Research Site
-
Yangzhou, Cina, 225001
- Reclutamento
- Research Site
-
Zhengzhou, Cina, 450000
- Reclutamento
- Research Site
-
Zhengzhou, Cina, 450008
- Reclutamento
- Research Site
-
-
-
-
-
Changwon, Corea del Sud, 51353
- Reclutamento
- Research Site
-
Incheon, Corea del Sud, 21565
- Reclutamento
- Research Site
-
Seongnam-si, Corea del Sud, 13496
- Reclutamento
- Research Site
-
Seoul, Corea del Sud, 03080
- Reclutamento
- Research Site
-
Seoul, Corea del Sud, 03722
- Reclutamento
- Research Site
-
Seoul, Corea del Sud, 08308
- Non ancora reclutamento
- Research Site
-
Seoul, Corea del Sud, 06973
- Reclutamento
- Research Site
-
Suwon, Corea del Sud, 16247
- Reclutamento
- Research Site
-
Suwon, Corea del Sud, 16499
- Reclutamento
- Research Site
-
-
-
-
-
Berlin, Germania, 10249
- Non ancora reclutamento
- Research Site
-
Bonn, Germania, 53113
- Reclutamento
- Research Site
-
Cologne, Germania, 50677
- Reclutamento
- Research Site
-
Düsseldorf, Germania, 40489
- Ritirato
- Research Site
-
Essen, Germania, 45136
- Reclutamento
- Research Site
-
Freiburg im Breisgau, Germania, 79106
- Reclutamento
- Research Site
-
Gauting, Germania, 82131
- Reclutamento
- Research Site
-
Georgsmarienhütte, Germania, 49124
- Ritirato
- Research Site
-
Gera, Germania, 07548
- Ritirato
- Research Site
-
Gütersloh, Germania, 33332
- Ritirato
- Research Site
-
Hamburg, Germania, 20251
- Reclutamento
- Research Site
-
Hamburg, Germania, 22087
- Reclutamento
- Research Site
-
Heidelberg, Germania, 69126
- Reclutamento
- Research Site
-
Kempten, Germania, 87439
- Sospeso
- Research Site
-
Kiel, Germania, 24116
- Non ancora reclutamento
- Research Site
-
Koblenz, Germania, 56068
- Sospeso
- Research Site
-
Ludwigsburg, Germania, 71640
- Ritirato
- Research Site
-
München, Germania, 81925
- Reclutamento
- Research Site
-
Nuremberg, Germania, 90419
- Ritirato
- Research Site
-
Potsdam, Germania, 14467
- Reclutamento
- Research Site
-
Ravensburg, Germania, 88212
- Reclutamento
- Research Site
-
-
-
-
-
Bunkyō City, Giappone, 113-8431
- Reclutamento
- Research Site
-
Bunkyō City, Giappone, 160-0023
- Reclutamento
- Research Site
-
Fukuoka, Giappone, 812-8582
- Reclutamento
- Research Site
-
Fukuoka, Giappone, 814-0180
- Reclutamento
- Research Site
-
Hakodate-shi, Giappone, 040-8611
- Reclutamento
- Research Site
-
Hidaka-shi, Giappone, 350-1298
- Reclutamento
- Research Site
-
Hirakata-shi, Giappone, 573-1191
- Reclutamento
- Research Site
-
Hirosaki-shi, Giappone, 036-8563
- Reclutamento
- Research Site
-
Hiroshima, Giappone, 730-8518
- Reclutamento
- Research Site
-
Kanazawa, Giappone, 920-8641
- Reclutamento
- Research Site
-
Kashiwa, Giappone, 227-8577
- Reclutamento
- Research Site
-
Kawasaki-shi, Giappone, 216-8511
- Reclutamento
- Research Site
-
Kumamoto, Giappone, 860-8556
- Reclutamento
- Research Site
-
Matsusaka-shi, Giappone, 515-8544
- Reclutamento
- Research Site
-
Matsuyama, Giappone, 790-0024
- Reclutamento
- Research Site
-
Nagoya, Giappone, 460-0001
- Reclutamento
- Research Site
-
Niigata, Giappone, 951-8566
- Reclutamento
- Research Site
-
Okayama, Giappone, 700-8558
- Reclutamento
- Research Site
-
Osaka, Giappone, 545-8586
- Ritirato
- Research Site
-
Osakasayama-shi, Giappone, 589-8511
- Reclutamento
- Research Site
-
Sagamihara-shi, Giappone, 252-0375
- Reclutamento
- Research Site
-
Sapporo, Giappone, 003-0804
- Reclutamento
- Research Site
-
Takaoka-shi, Giappone, 933-8555
- Reclutamento
- Research Site
-
Takatsuki-shi, Giappone, 569-8686
- Reclutamento
- Research Site
-
Tokushima, Giappone, 770-8503
- Reclutamento
- Research Site
-
Tokyo, Giappone, 104-0045
- Reclutamento
- Research Site
-
Utsunomiya, Giappone, 320-0834
- Reclutamento
- Research Site
-
Yokohama, Giappone, 221-0855
- Reclutamento
- Research Site
-
-
-
-
-
Chennai, India, 600031
- Reclutamento
- Research Site
-
Dwārka, India, 110075
- Reclutamento
- Research Site
-
Jaipur, India, 302004
- Reclutamento
- Research Site
-
Kolkata, India, 700099
- Reclutamento
- Research Site
-
Marg Jaipur, India, 302004
- Ritirato
- Research Site
-
Nagpur, India, 440001
- Reclutamento
- Research Site
-
Nashik, India, 422011
- Reclutamento
- Research Site
-
New Delhi, India, 11029
- Reclutamento
- Research Site
-
New Delhi, India, 110085
- Reclutamento
- Research Site
-
Surat, India, 395002
- Reclutamento
- Research Site
-
Thiruvananthapuram, India, 695011
- Ritirato
- Research Site
-
-
-
-
-
Bergamo, Italia, 24125
- Reclutamento
- Research Site
-
Genoa, Italia, 16132
- Reclutamento
- Research Site
-
Milan, Italia, 20141
- Reclutamento
- Research Site
-
Milan, Italia, 20162
- Reclutamento
- Research Site
-
Monza, Italia, 20052
- Reclutamento
- Research Site
-
Padova, Italia, 35128
- Reclutamento
- Research Site
-
Pavia, Italia, 27100
- Reclutamento
- Research Site
-
Ravenna, Italia, 48100
- Reclutamento
- Research Site
-
Roma, Italia, 00128
- Reclutamento
- Research Site
-
Rozzano, Italia, 20089
- Reclutamento
- Research Site
-
-
-
-
-
Olsztyn, Polonia, 10-357
- Reclutamento
- Research Site
-
Poznan, Polonia, 60-569
- Reclutamento
- Research Site
-
Przemyśl, Polonia, 37-700
- Reclutamento
- Research Site
-
Warsaw, Polonia, 02-781
- Reclutamento
- Research Site
-
Warsaw, Polonia, 01-138
- Reclutamento
- Research Site
-
-
-
-
-
San Juan, Porto Rico, 00909
- Reclutamento
- Research Site
-
-
-
-
-
Cheltenham, Regno Unito, GL53 7AN
- Sospeso
- Research Site
-
Inverness, Regno Unito, IV2 3UJ
- Sospeso
- Research Site
-
London, Regno Unito, SW17 0QT
- Reclutamento
- Research Site
-
London, Regno Unito, SW10 9NH
- Reclutamento
- Research Site
-
London, Regno Unito, SE1 9RT
- Ritirato
- Research Site
-
Norwich, Regno Unito, NR4 7UY
- Reclutamento
- Research Site
-
Preston, Regno Unito, PR2 9HT
- Reclutamento
- Research Site
-
Truro, Regno Unito, TR1 3LJ
- Reclutamento
- Research Site
-
-
-
-
-
Alicante, Spagna, 03010
- Reclutamento
- Research Site
-
Barcelona, Spagna, 08036
- Reclutamento
- Research Site
-
Barcelona, Spagna, 08003
- Reclutamento
- Research Site
-
Barcelona, Spagna, 08041
- Non ancora reclutamento
- Research Site
-
Jerez de la Frontera, Spagna, 11407
- Reclutamento
- Research Site
-
Reus, Spagna, 43204
- Reclutamento
- Research Site
-
Salamanca, Spagna, 37007
- Ritirato
- Research Site
-
-
-
-
Alaska
-
Anchorage, Alaska, Stati Uniti, 99508
- Reclutamento
- Research Site
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85719
- Reclutamento
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72205
- Reclutamento
- Research Site
-
Springdale, Arkansas, Stati Uniti, 72762
- Reclutamento
- Research Site
-
-
California
-
Anaheim, California, Stati Uniti, 92801
- Reclutamento
- Research Site
-
Beverly Hills, California, Stati Uniti, 90211
- Reclutamento
- Research Site
-
Fountain Valley, California, Stati Uniti, 92708
- Reclutamento
- Research Site
-
Newport Beach, California, Stati Uniti, 92663
- Sospeso
- Research Site
-
-
Florida
-
Clermont, Florida, Stati Uniti, 34711
- Reclutamento
- Research Site
-
Gainesville, Florida, Stati Uniti, 32608
- Reclutamento
- Research Site
-
Miami Beach, Florida, Stati Uniti, 33140
- Reclutamento
- Research Site
-
Orange City, Florida, Stati Uniti, 32763
- Reclutamento
- Research Site
-
Orlando, Florida, Stati Uniti, 32806
- Reclutamento
- Research Site
-
Orlando, Florida, Stati Uniti, 32827
- Ritirato
- Research Site
-
West Palm Beach, Florida, Stati Uniti, 33401
- Reclutamento
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- Research Site
-
Atlanta, Georgia, Stati Uniti, 30318
- Reclutamento
- Research Site
-
Atlanta, Georgia, Stati Uniti, 30342
- Ritirato
- Research Site
-
Atlanta, Georgia, Stati Uniti, 30303
- Sospeso
- Research Site
-
-
Illinois
-
Hinsdale, Illinois, Stati Uniti, 60521
- Reclutamento
- Research Site
-
-
Indiana
-
Noblesville, Indiana, Stati Uniti, 46062
- Reclutamento
- Research Site
-
-
Kentucky
-
Paducah, Kentucky, Stati Uniti, 42003
- Reclutamento
- Research Site
-
-
Maryland
-
Annapolis, Maryland, Stati Uniti, 21401
- Reclutamento
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Reclutamento
- Research Site
-
Boston, Massachusetts, Stati Uniti, 02114
- Reclutamento
- Research Site
-
-
Michigan
-
Dearborn, Michigan, Stati Uniti, 48126
- Reclutamento
- Research Site
-
Farmington Hills, Michigan, Stati Uniti, 48334
- Reclutamento
- Research Site
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Reclutamento
- Research Site
-
Traverse City, Michigan, Stati Uniti, 49684
- Ritirato
- Research Site
-
-
Mississippi
-
Hattiesburg, Mississippi, Stati Uniti, 39401
- Reclutamento
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64132
- Reclutamento
- Research Site
-
-
Montana
-
Bozeman, Montana, Stati Uniti, 59715
- Ritirato
- Research Site
-
-
Nebraska
-
Grand Island, Nebraska, Stati Uniti, 68803
- Reclutamento
- Research Site
-
Omaha, Nebraska, Stati Uniti, 68130
- Reclutamento
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89102
- Reclutamento
- Research Site
-
Reno, Nevada, Stati Uniti, 89502
- Ritirato
- Research Site
-
-
New Jersey
-
Voorhees Township, New Jersey, Stati Uniti, 08043
- Sospeso
- Research Site
-
-
New York
-
Stony Brook, New York, Stati Uniti, 11794
- Reclutamento
- Research Site
-
-
North Carolina
-
Greenville, North Carolina, Stati Uniti, 27834
- Reclutamento
- Research Site
-
Salisbury, North Carolina, Stati Uniti, 28144
- Reclutamento
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45219
- Reclutamento
- Research Site
-
Columbus, Ohio, Stati Uniti, 43210
- Ritirato
- Research Site
-
Maumee, Ohio, Stati Uniti, 43537
- Reclutamento
- Research Site
-
Toledo, Ohio, Stati Uniti, 43623
- Reclutamento
- Research Site
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97213
- Ritirato
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, Stati Uniti, 29607
- Reclutamento
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57105
- Reclutamento
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, Stati Uniti, 37404
- Ritirato
- Research Site
-
Knoxville, Tennessee, Stati Uniti, 37920
- Ritirato
- Research Site
-
-
Texas
-
Fort Worth, Texas, Stati Uniti, 76104
- Reclutamento
- Research Site
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Research Site
-
Houston, Texas, Stati Uniti, 77030
- Ritirato
- Research Site
-
Houston, Texas, Stati Uniti, 77090
- Sospeso
- Research Site
-
Kingwood, Texas, Stati Uniti, 77339
- Reclutamento
- Research Site
-
Odessa, Texas, Stati Uniti, 79761
- Reclutamento
- Research Site
-
-
Virginia
-
Fort Belvoir, Virginia, Stati Uniti, 22060
- Reclutamento
- Research Site
-
Leesburg, Virginia, Stati Uniti, 20176
- Reclutamento
- Research Site
-
Midlothian, Virginia, Stati Uniti, 23114
- Reclutamento
- Research Site
-
Richmond, Virginia, Stati Uniti, 23230
- Reclutamento
- Research Site
-
-
Washington
-
Tacoma, Washington, Stati Uniti, 98405
- Reclutamento
- Research Site
-
Vancouver, Washington, Stati Uniti, 98684
- Reclutamento
- Research Site
-
Wenatchee, Washington, Stati Uniti, 98801
- Reclutamento
- Research Site
-
-
Wisconsin
-
Appleton, Wisconsin, Stati Uniti, 54911
- Reclutamento
- Research Site
-
-
-
-
-
Bangkok, Tailandia, 10400
- Reclutamento
- Research Site
-
Bangkok, Tailandia, 10700
- Reclutamento
- Research Site
-
Hat Yai, Tailandia, 90110
- Reclutamento
- Research Site
-
Muang, Tailandia, 22000
- Reclutamento
- Research Site
-
Mueang, Tailandia, 20000
- Reclutamento
- Research Site
-
Mueang, Tailandia, 32000
- Reclutamento
- Research Site
-
-
-
-
-
Changhua, Taiwan, 500
- Non ancora reclutamento
- Research Site
-
Kaohsiung City, Taiwan, 80756
- Reclutamento
- Research Site
-
New Taipei City, Taiwan, 220
- Reclutamento
- Research Site
-
Taichung, Taiwan, 40447
- Reclutamento
- Research Site
-
Taichung, Taiwan, 40705
- Reclutamento
- Research Site
-
Tainan, Taiwan, 704
- Reclutamento
- Research Site
-
Taipei, Taiwan, TAIWAN
- Reclutamento
- Research Site
-
Taipei, Taiwan, 10002
- Reclutamento
- Research Site
-
Taipei, Taiwan, 112
- Reclutamento
- Research Site
-
Taipei, Taiwan, 0116
- Reclutamento
- Research Site
-
Taoyuan, Taiwan, 333
- Reclutamento
- Research Site
-
-
-
-
-
Adapazarı, Turchia (Türkiye), 54100
- Reclutamento
- Research Site
-
Ankara, Turchia (Türkiye), 6200
- Reclutamento
- Research Site
-
Ankara, Turchia (Türkiye), 06560
- Reclutamento
- Research Site
-
Antalya, Turchia (Türkiye), 07070
- Reclutamento
- Research Site
-
Diyarbakır, Turchia (Türkiye), 21280
- Reclutamento
- Research Site
-
Istanbul, Turchia (Türkiye), 34030
- Reclutamento
- Research Site
-
Istanbul, Turchia (Türkiye), 34890
- Reclutamento
- Research Site
-
-
-
-
-
Budapest, Ungheria, 1121
- Reclutamento
- Research Site
-
Edelény, Ungheria, 3780
- Non ancora reclutamento
- Research Site
-
Gyula, Ungheria, 5700
- Sospeso
- Research Site
-
Gyöngyös, Ungheria, 3200
- Ritirato
- Research Site
-
Gyöngyös - Mátraháza, Ungheria, 3200
- Reclutamento
- Research Site
-
Győr, Ungheria, 9024
- Reclutamento
- Research Site
-
Kecskemét, Ungheria, 6000
- Reclutamento
- Research Site
-
Salgótarján, Ungheria, 3100
- Ritirato
- Research Site
-
Szekszárd, Ungheria, 7100
- Reclutamento
- Research Site
-
Szolnok, Ungheria, 5000
- Ritirato
- Research Site
-
Székesfehérvár, Ungheria, 8000
- Ritirato
- Research Site
-
Törökbálint, Ungheria, 2045
- Reclutamento
- Research Site
-
-
-
-
-
Da Nang, Vietnam, 550000
- Reclutamento
- Research Site
-
Hanoi, Vietnam, 100000
- Reclutamento
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Reclutamento
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Ritirato
- Research Site
-
Huế, Vietnam, 530000
- Ritirato
- Research Site
-
Hà Nội, Vietnam, 100000
- Reclutamento
- Research Site
-
Vinh, Vietnam, 460000
- Ritirato
- Research Site
-
Vĩnh Yên, Vietnam, 280000
- Reclutamento
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologically or cytologically documented non-squamous NSCLC.
- Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation.
- Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and absence of documented local test result for any other known genomic alteration for which there are locally approved and available targeted first-line therapies.
- Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers.
- Known tumour PD-L1 expression status defined as TC ≥ 50%
- At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline
- ECOG performance status of 0 or 1
- Adequate bone marrow reserve and organ function
Exclusion Criteria:
- Prior systemic therapy for advanced/metastatic NSCLC.
- Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant.
- History of another primary malignancy within 3 years
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Any evidence of severe or uncontrolled disease that makes it undesirable for the participant to participate in the study or that would jeopardies compliance with the protocol.
- Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage.
- History of any ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, has current or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- Has significant pulmonary function compromise, as determined by the investigator
- Spinal cord compression, or brain metastases unless participant treated and no longer symptomatic, radiologically stable, and who require no treatment with corticosteroids or anticonvulsants.
- History of leptomeningeal carcinomatosis
- Known clinically significant corneal disease
- Active infection with TB, HBV, HCV, Hepatitis A, or known HIV infection that is not well controlled
- History of active primary immunodeficiency
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Arm 1: Datopotamab Deruxtecan in Combination With Rilvegostomig
Participants in the Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig group will receive Dato-DXd plus rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Datopotamab Deruxtecan IV (intravenous)
Altri nomi:
Rilvegostomig IV (intravenous)
Altri nomi:
|
|
Sperimentale: Arm 2: Rilvegostomig Monotherapy
Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Rilvegostomig IV (intravenous)
Altri nomi:
|
|
Comparatore attivo: Arm 3: Pembrolizumab Monotherapy
Participants in the pembrolizumab group will receive pembrolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle. |
Pembrolizumab IV (intravenous)
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-Free Survival (PFS) in TROP2 biomarker positive participants.
Lasso di tempo: Approximately 4 years
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population: • TROP2 biomarker positive population The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Overall Survival (OS) in TROP2 biomarker positive participants.
Lasso di tempo: Approximately 6 years
|
OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population: • TROP2 biomarker positive population The measure of interest is the HR of OS. |
Approximately 6 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-Free Survival (PFS) in the FAS population.
Lasso di tempo: Approximately 4 years
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population: • FAS population The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Overall Survival (OS) in the FAS population.
Lasso di tempo: Approximately 6 years
|
OS is defined as the time from randomisation until the date of death due to any cause. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population: • FAS population The measure of interest is the HR of OS. |
Approximately 6 years
|
|
Assessment of Objective Response Rate (ORR) by BICR in TROP2 biomarker positive and FAS populations
Lasso di tempo: Approximately 4 years
|
ORR is defined as the proportion of participants who have a CR or PR, as determined by BICR per RECIST 1.1. The analyses will include all randomised participants, as randomised, with measurable disease at baseline, in the following populations:
The measure of interest is the difference of the ORR. ORR by investigator will be reported as a sensitivity analysis. |
Approximately 4 years
|
|
Assessment of Duration of Response (DoR) by BICR in TROP2 biomarker positive and FAS populations
Lasso di tempo: Approximately 4 years
|
DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR or death due to any cause. The analyses will include all randomised participants who have a response, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following populations:
|
Approximately 4 years
|
|
Participant-reported lung cancer symptoms of NSCLC and participant-reported GHS/QOL in participants treated with Dato-DXd in combination with rilvegostomig relative to pembrolizumab.
Lasso di tempo: Approximately 6 years
|
Time to deterioration in: pulmonary symptoms (dyspnoea, cough, and chest pain) as measured by the NSCLC-SAQ, in overall lung cancer symptoms as measured by the NSCLC-SAQ, and in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172. Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:
|
Approximately 6 years
|
|
Participant-reported physical functioning in participants treated with Dato DXd in combination with rilvegostomig relative to pembrolizumab.
Lasso di tempo: Approximately 6 years
|
Time to deterioration in physical functioning as measured by PROMIS Physical Function short form 8c. Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:
|
Approximately 6 years
|
|
Pharmacokinetics (PK)
Lasso di tempo: Approximately 6 years
|
Concentration of rilvegostomig, Dato-DXd, total anti TROP2 antibody, and MAAA 1181a (payload deruxtecan) in plasma or serum and PK parameters (peak and trough concentrations). |
Approximately 6 years
|
|
Immunogenicity
Lasso di tempo: Approximately 6 years
|
Presence of ADA for Dato-DXd and rilvegostomig (confirmatory results, titres and neutralising antibodies for confirmed positive samples). |
Approximately 6 years
|
|
Second Progression-Free Survival (PFS2).
Lasso di tempo: Approximately 6 years
|
PFS2 is defined as the time from randomisation to the earliest of the progression events (following the initial progression), subsequent to first subsequent therapy, or death. Progression event includes radiological (RECIST 1.1) or clinical disease progression. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard practice. The analyses will include all randomised participants, as randomised, regardless of whether the participant withdraws from subsequent therapy and regardless of missed visits, in the following populations:
|
Approximately 6 years
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety of Dato-DXd in combination with rilvegostomig and rilvegostomig monotherapy as compared with pembrolizumab.
Lasso di tempo: Approximately 6 years
|
Safety and tolerability will be evaluated in terms of AEs (graded by CTCAE Version 5.0). |
Approximately 6 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Suresh S. Ramalingam, MD, Emory University, Atlanta, Georgia, United States of America.
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- D7632C00001
- 2023-505077-32-00 (Identificatore di registro: CTIS (EU))
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Periodo di condivisione IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Criteri di accesso alla condivisione IPD
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool .
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .